SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (“ACI”) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.
The company is looking for talented, motivated, dynamic employees to join its international team, who will have the opportunity to utilize and further develop their own abilities.
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
Dortmund, Germany and Prague, Czech Republic, April 11, 2017 – The Lead Discovery Center GmbH...